May 19, 2020

Former BHP Billiton Boss Alberto Calderon Takes Over as Orica's Interim CEO

We Photo Booth You
2 min
Former BHP Billiton Boss Alberto Calderon Takes Over as Orica's Interim CEO

Orica—the world’s biggest supplier of mining explosives—has been busy. Last week the company shared that Ian Smith, former CEO, was going to be replaced. He would stay on for as long as was required to find a new person for the position, but it turns out that it wasn’t going to be long.

Just today Orica announced Alberto Calderon, former boss of BHP Billiton’s aluminium, nickel and corporate development divisions, will take over as interim CEO. Calderon has been on Orica’s board since August 2013.

The company issued a statement with the decision, saying that the board and Smith had "agreed that in the interests of minimising further distractions and enabling Orica to move on," Mr Smith should leave the company immediately.

The “distractions” mentioned include a series of incidents with staff in recent months. Smith himself had even admitted to his sometimes aggressive and confrontational management style, which has not gelled with Orica’s company strategy for the future.

 "I'm extremely disappointed. I was changing and there was an incident that coloured where we were going [as an organisation]. Sometimes I go beyond being robust and become aggressive," Smith said.

Read related articles from Business Review Australia:
How Do You Make Mining Better? Unearthed Thinks Tech Startups Hold the Key
As 50,000 Mining Jobs Go, Construction and Services Open Doors to Workers

The incident in question was an aggressive outburst aimed at the general manager of investor relations in January of this year, which precipitated this week’s actions by Orica.

Calderon comes on to Orica during a period of transition for the industry, where Orica will have to fight to maintain its margins in the face of much lower commodity prices.

The "importance of ensuring stability and operational continuity at Orica has been at the forefront of my discussions with the board,” said Calderon. "The ongoing implementation of our strategy will be my priority while the board continues the process of selecting a permanent CEO.”

Join us on Facebook.
Like us on Twitter.

Information sourced from Financial Review.

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”


Share article